Jun 09, 2020
Enteris BioPharma Announces Dr. John Vrettos to Participate in BIODURO Webinar Series
Jun 02, 2020
Enteris BioPharma to Participate in BIO International Digital Convention
May 04, 2020
Enteris BioPharma Appoints Rajiv Khosla, Ph.D., as Chief Executive Officer
Feb 10, 2020
Enteris BioPharma Appoints Gary A. Shangold, MD, as Chief Medical Officer
Jan 27, 2020
Enteris BioPharma Receives 2019 Best of Boonton Award
Dec 06, 2019
Enteris BioPharma's Licensing Partner, Cara Therapeutics, Announces Top Line Data from Phase 2 Trial of Peptelligence®-Engineered Oral KORSUVA(TM) for the Treatment of Pruritus in Patients with Advanced Chronic Kidney Disease (CKD)
Aug 27, 2019
SWK Holdings Corporation Acquires Enteris BioPharma
Aug 21, 2019
Enteris BioPharma and Cara Therapeutics Enter into Licensing Agreement for Peptelligence® to Advance Development of Oral KORSUVA(TM)
Jun 27, 2019
Enteris BioPharma's "Feasibility-to-Licensing" Partner, Cara Therapeutics, Initiates Second Pruritus Phase 2 Trial of Peptelligence®-Engineered Oral KORSUVA(TM)
Mar 05, 2019
Enteris BioPharma Supports Endometriosis Awareness Month
Dec 18, 2018
Enteris BioPharma to Present at Biotech Showcase 2019
Jul 19, 2018
Enteris BioPharma's "Feasibility-to-Licensing" Partner, Cara Therapeutics, Doses First Patient in Phase 2 Trial of Peptelligence®-Engineered Oral KORSUVA(TM)
Jun 26, 2018
Enteris BioPharma Announces Positive Results from Expanded Phase 2a Clinical Trial of Ovarest® (oral leuprolide tablet) for Endometriosis
Mar 15, 2018
Enteris BioPharma to Present at the 25th Annual Future Leaders in the Biotech Industry Conference
Mar 05, 2018
Enteris BioPharma Initiates Feasibility Program with Ferring Pharmaceuticals to Develop an Oral Formulation of a Peptide
Mar 01, 2018
Enteris BioPharma's "Feasibility-to-Licensing" Partner, Cara Therapeutics, Doses First Patient in Phase 1 Trial of Oral KORSUVA(TM)
Jan 03, 2018
Enteris BioPharma Announces Positive Results from Phase 2a Clinical Trial of Ovarest® (oral leuprolide tablet) for Endometriosis
Oct 31, 2017
Enteris BioPharma's "Feasibility-to-Licensing" Partner, Cara Therapeutics, Doses First Patient in Phase 1 Study of Peptelligence(TM)-Engineered Oral CR845 in Non-Hemodialysis Chronic Kidney Disease Patients
Sep 19, 2017
Enteris BioPharma to Present at BioPharm America
Aug 24, 2017
Enteris BioPharma Doses First Woman in Phase 2a Clinical Trial of Ovarest(TM) (oral leuprolide tablet) for Endometriosis